Peptide drug intermediates are building blocks formed by amino acids via peptide bonds, playing a pivotal role in peptide drug development. In peptide synthesis, amino acids are typically used as starting materials. To enhance efficiency and cost-effectiveness, protected oligopeptides can also be utilised as starting materials for complex peptides. These intermediates undergo precise sequence design and modification to optimise biological activity, stability, and pharmacokinetic properties. Typically, these intermediates are prepared via solid-phase peptide synthesis (SPPS) or liquid-phase methods, and are then subjected to rigorous purification (e.g., high-performance liquid chromatography) in order to ensure high purity (>95%) and to eliminate by-products. The market launch of GLP-1 peptide drugs such as semaglutide has substantially increased demand for peptide drug intermediates. Besides, advancements in automated synthesis technologies and green chemistry methods continue to enhance cost-effectiveness and scalability, establishing peptide drug intermediates as indispensable tools in peptide-based drug development.

click to sign in and save
A752235957780-56-295%
Fmoc-Glu(OtBu)-Thr(psi(Me,Me)pro)-OH$28.00/250mg Detail
click to sign in and save
A378596957780-59-598% (HPLC)
Fmoc-Asn(Trt)-Thr(psi(Me,Me)pro)-OH$98.00/1g Detail
click to sign in and save
A13061550N/A99%
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-((2,4-dimethoxybenzyl)oxy)phenyl)propanoic acid$0.00/1kg Detail
click to sign in and save
A2946195N/A99%
Boc-L-His(Trt)-1-Aminocyclobutanecarboxylic acid$0.00/500kg Detail


















